{"id":"gadovist-gadavist","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Gadolinium retention (in patients with renal impairment)"}]},"_chembl":{"chemblId":"CHEMBL2218860","moleculeType":"Small molecule","molecularWeight":"604.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gadovist contains gadolinium, a paramagnetic metal ion that is chelated with a ligand (gadoterate meglumine) to create a stable complex. When injected intravenously, it distributes through the body and accumulates in areas of interest, altering the magnetic properties of nearby water molecules to increase signal intensity on T1-weighted MRI images, thereby improving visualization of anatomical structures and pathology.","oneSentence":"Gadovist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:56.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contrast enhancement for MRI of the central nervous system (brain and spinal cord)"},{"name":"Contrast enhancement for MRI of the body (organs, tissues, and vasculature)"}]},"trialDetails":[{"nctId":"NCT05229744","phase":"","title":"Prevalence of Endolymphatic Hydrops With a Hitory of Congenital Cytomegalovirus Infection","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-12-15","conditions":"Endolymphatic Hydrops","enrollment":18},{"nctId":"NCT07040865","phase":"PHASE4","title":"Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-08-18","conditions":"Suspect Renal and Adrenal Imaging Findings","enrollment":104},{"nctId":"NCT02358811","phase":"","title":"Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-06-30","conditions":"Obstructive Sleep Apnea (SAOS), Aging","enrollment":69},{"nctId":"NCT04350957","phase":"NA","title":"Low-dose Imaging Technique (LITE)","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2020-08-24","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT02917213","phase":"","title":"Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2016-09","conditions":"Myocardial Infarction, Acute Disease, Thrombosis","enrollment":92},{"nctId":"NCT04949321","phase":"NA","title":"Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear.","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2021-07-31","conditions":"Inner Ear ; Meniere's Disease; Imaging","enrollment":80},{"nctId":"NCT03404648","phase":"PHASE3","title":"Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-11-01","conditions":"Prostate Adenocarcinoma","enrollment":19},{"nctId":"NCT01655290","phase":"PHASE2","title":"Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2012-08","conditions":"Subacute/Chronic Myocardial Infarction","enrollment":20},{"nctId":"NCT03057561","phase":"NA","title":"Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance","status":"UNKNOWN","sponsor":"Dipan Shah","startDate":"2016-10-01","conditions":"Coronary Artery Disease, Cardiomyopathy","enrollment":120},{"nctId":"NCT02034708","phase":"PHASE4","title":"Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors","status":"COMPLETED","sponsor":"Guerbet","startDate":"2014-06","conditions":"Primary Brain Tumor","enrollment":279},{"nctId":"NCT02274246","phase":"PHASE1","title":"Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2014-11","conditions":"Left Atrial Fibrosis","enrollment":9},{"nctId":"NCT01613417","phase":"PHASE4","title":"Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2012-08","conditions":"Brain Disease","enrollment":229},{"nctId":"NCT00764387","phase":"PHASE4","title":"Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-03","conditions":"Neoplastic CNS Lesions","enrollment":166},{"nctId":"NCT01104584","phase":"PHASE3","title":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Breast Cancer","enrollment":460},{"nctId":"NCT01067976","phase":"PHASE3","title":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-02","conditions":"Breast Cancer, Diagnostic Imaging","enrollment":446},{"nctId":"NCT01490294","phase":"PHASE2","title":"Myocardial Perfusion MRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Myocardial Perfusion Imaging, Magnetic Resonance Imaging","enrollment":232},{"nctId":"NCT00874640","phase":"","title":"Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Epidemiologic Factors","enrollment":3711},{"nctId":"NCT01026389","phase":"PHASE4","title":"Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease","status":"COMPLETED","sponsor":"Guerbet","startDate":"2009-10","conditions":"Peripheral Arterial Disease","enrollment":189},{"nctId":"NCT00955617","phase":"PHASE4","title":"DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases","status":"COMPLETED","sponsor":"Guerbet","startDate":"2009-07","conditions":"Peripheral Arterial Disease","enrollment":20},{"nctId":"NCT00907530","phase":"PHASE4","title":"Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2009-09","conditions":"Brain Lesions","enrollment":121},{"nctId":"NCT00549861","phase":"NA","title":"Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR","status":"COMPLETED","sponsor":"Oliver Strohm","startDate":"2007-09","conditions":"Cardiomyopathy, Dilated, Cardiomyopathies, Secondary","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gadovist®/Gadavist®","genericName":"Gadovist®/Gadavist®","companyName":"Guerbet","companyId":"guerbet","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadovist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues. Used for Contrast enhancement for MRI of the central nervous system (brain and spinal cord), Contrast enhancement for MRI of the body (organs, tissues, and vasculature).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}